Founded in 2016 by a patient family, the RUNX1 Research Program’s mission is to support patients with RUNX1 Familial Platelet Disorder (RUNX1- FPD) by empowering our patient community and funding innovative, world-class research laser focused on preventing cancer. RUNX1-FPD is a rare hereditary blood disorder which predisposes an individual to developing blood cancer with a rate 30 times higher than the general population.

The RUNX1 Research Program has quickly worked to fill the massive medical research and public awareness gaps that exist around this disease and similar hereditary cancer mutations. Anyone can have RUNX1-FPD. Although considered a rare disorder, the frequency of RUNX1-FPD has been historically underestimated. We are committed to building awareness around the disease and amplifying the patient voice. RRP is the only non-profit organization worldwide that advocates and funds RUNX1-FPD research. RRP has committed over $9M in research grants aimed at understanding how inherited mutations predispose individuals to blood cancers. This important work has broad implications for cancer prevention in the general population as well.

RUNX1 Research Program

Organization Details